Hypertensive disorders complicate an estimated 6-8% of all pregnancies and are a significant source of fetal and maternal morbidity and mortality. Approximately 3-4% of all pregnant women will be exposed to antihypertensive medications during pregnancy. The antihypertensive most commonly used in pregnancy in the United States is methyldopa;however, it is an older, often poorly tolerated medication. It may be an inferior therapy with respect to important pregnancy outcomes compared to other classes of agents including alpha-beta blockers, beta blockers, and calcium channel blockers. Yet, for each of these other classes, important fetal safety concerns have been raised. The primary goal of the proposed project is therefore to evaluate the comparative safety and effectiveness of each of these commonly used agents relative to methyldopa. The clinical question this study aims to address is: "If a patient requires an outpatient antihypertensive during pregnancy for pre-existing or gestational hypertension, what is the safest agent for the fetus, and the one most likely to assure a good pregnancy outcome?" We will also examine the safety of first trimester exposure to thiazide diuretics and angiotensin converting enzyme inhibitors, which are the most common types of antihypertensives used in women of reproductive age outside of pregnancy and thus common first trimester exposures. This analysis will address the clinical question: "For a woman in whom pregnancy is planned or possible, which agents can be safely used given the potential for early fetal exposure to the medication?" The study will be performed using a pregnancy cohort obtained from the Medicaid Analytic Extract (MAX), a large population-based claims database. Using this dataset, we have developed a cohort of over 1.1 million pregnancies with longitudinal data that span from the pre-pregnancy to the postpartum periods. This cohort is linked to outpatient pharmacy claims and fetal records making it an exceptionally well-suited data source for the kind of study we propose. I will perform the proposed research within the well developed infrastructure of the Division of Pharmacoepidemiology and Pharmacoeconomics ("The Division") at the Brigham and Women's Hospital. The Division has a long track record of producing outstanding drug safety and effectiveness research using observational data sources. I will work with an interdisciplinary team of mentors and collaborators drawn from across institutions at Harvard University that have deep expertise and national/international reputations in epidemiological and statistical methods, perinatal pharmacoepidemiology, high-risk obstetrics, hypertensive diseases, and drug policy. This research work will be complemented by formal coursework at the Harvard School of Public Health and frequent seminars and lab meetings at the Division. This combination of intensive research, mentoring, and formal education will provide the necessary background for me to become a successful, independent researcher in obstetric pharmacoepidemiology.

Public Health Relevance

About 4% of all pregnant women will take an antihypertensive medication during pregnancy. Much is unknown about the comparative safety and effectiveness of different antihypertensives in pregnancy. The present study aims to define the class of antihypertensive agent that is safest for the fetus and the one most likely to assure a good pregnancy outcome.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08HD075831-02
Application #
8625804
Study Section
Pediatrics Subcommittee (CHHD)
Program Officer
Zajicek, Anne
Project Start
2013-04-01
Project End
2018-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
2
Fiscal Year
2014
Total Cost
$137,160
Indirect Cost
$10,160
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Patorno, Elisabetta; Wang, Shirley V; Schneeweiss, Sebastian et al. (2016) Initiation patterns of statin therapy among adult patients undergoing intermediate to high-risk non-cardiac surgery. Pharmacoepidemiol Drug Saf 25:64-72
Baker, James A; Avorn, Jerry; Levin, Raisa et al. (2016) Opioid Prescribing After Surgical Extraction of Teeth in Medicaid Patients, 2000-2010. JAMA 315:1653-4
Ladha, Karim S; Patorno, Elisabetta; Liu, Jun et al. (2016) Impact of Perioperative Epidural Placement on Postdischarge Opioid Use in Patients Undergoing Abdominal Surgery. Anesthesiology 124:396-403
Bateman, Brian T; Franklin, Jessica M; Bykov, Katsiaryna et al. (2016) Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naïve women. Am J Obstet Gynecol 215:353.e1-353.e18
Rough, Kathryn; Bateman, Brian T; Patorno, Elisabetta et al. (2016) Suppression of Substance Abuse Claims in Medicaid Data and Rates of Diagnoses for Non-Substance Abuse Conditions. JAMA 315:1164-6
Ladha, Karim S; Patorno, Elisabetta; Huybrechts, Krista F et al. (2016) Variations in the Use of Perioperative Multimodal Analgesic Therapy. Anesthesiology 124:837-45
Gudnadóttir, Thuridur A; Bateman, Brian T; Hernádez-Díaz, Sonia et al. (2016) Body Mass Index, Smoking and Hypertensive Disorders during Pregnancy: A Population Based Case-Control Study. PLoS One 11:e0152187
Desai, Rishi J; Huybrechts, Krista F; Bateman, Brian T et al. (2016) Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions. Arthritis Rheumatol 68:1183-9
Phiri, Kelesitse; Hernandez-Diaz, Sonia; Tsen, Lawrence C et al. (2015) Accuracy of ICD-9-CM coding to identify small for gestational age newborns. Pharmacoepidemiol Drug Saf 24:381-8
Patorno, Elisabetta; Wang, Shirley V; Schneeweiss, Sebastian et al. (2015) Patterns of β-blocker initiation in patients undergoing intermediate to high-risk noncardiac surgery. Am Heart J 170:812-820.e6

Showing the most recent 10 out of 28 publications